MedX Health Exploring Clinical Applications of its SIAscopy, DermSecure Tech

MedX Health Corp. is looking to expand the clinical use of its dermatological image capture technology and patient management system in North America.

The company has consulted with medical advisory boards comprised of leading dermatologists to explore potential opportunities to use its SIAscopy and patient management system DermSecure in clinical settings. Findings from the advisory boards will help validate the technological uses and benefits of SIAscopy in clinical practice, particularly as a triage tool for dermatological assessment of suspicious moles and lesions. The boards’ recommendations will be compiled and published in the coming months through separate publications pertaining to the Canadian and U.S. markets.
 
“This technology has the potential to save many lives as an effective triage tool,” said Dr. Daniel Siegel, chair of the U.S.-based Medical Advisory Board. “Scanning more at-risk patients in easy to access locations will provide greater early detection of cancerous and pre-cancerous lesions, providing better patient outcomes while lowering overall healthcare costs. MedX’s DermSecure platform offers a very complete teledermatology solution—with their unique imaging technology, they can provide dermatologists with high resolution images of pigmented lesions for evaluation along with multispectral images that enhance diagnostic accuracy. Until now, most teledermatology offerings could not provide high quality images of potentially deadly melanomas to dermatologists for assessment.”

MedX’s SIAscopy is the only technology on the market that captures five high resolution images, including four spectrophotometric images 2mm below the skin’s surface, enabling dermatological assessment of suspicious moles and lesions in a pain-free, non-invasive manner. Combined with MedX’s DermSecure Screening Platform—its secure, cloud-based patient management system—these high resolution images are transmitted safely and securely for virtual dermatological assessment by a certified dermatologist within just 72 hours, compared to a wait time of five months to one year for traditional dermatological assessment.

A similar medical advisory board consultation process is also underway in the United Kingdom, which will be followed by the formation of such an advisory body in Europe.
 
“This technology shows tremendous promise for positively impacting patient care, particularly as a tool for patients and clinicians seeking second opinions. Because of the quality of SIAscopy’s high resolution images, we’re also interested in its potential for assessing a wide range of additional skin conditions,” said Dr. Charles Lynde, chair of the Canadian-based Medical Advisory Board. 

MedX, headquartered in Ontario, Canada, focuses on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also embedded in its products SIAMETRICS, SIMSYS, and MoleMate, which MedX manufactures in its ISO 13485-certified facility. SIAMETRICS, SIMSYS, and MoleMate include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain-free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are approved by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the United States, Australia, New Zealand, the European Union, Brazil, and Turkey.